Epoetin alfa HEXAL® in Chemotherapy induced Anaemia and Evolution of Cardiomyopathy under Anthracyclines - A non-interventional study

HEXAL AG0 个研究点目标入组 2 人开始时间: 2012年6月29日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Male or female patients at least 18 years old with solid tumours, malignant lymphomas or multiple myeloma, who are treated with an anthracycline containing chemotherapy, have not yet received epoetins in the current chemotherapy line and receive Epoetin alfa HEXAL for the first time in this chemotherapy line for symptomatic anaemia.
•2. Therapy with Epoetin alfa HEXAL is planned for two to six chemotherapy cycles.
•3. Echocardiography with quantitative assessment of LVEF (in %) has been performed at the start of anthracycline based chemotherapy.
•4. At least one further echocardiography with quantitative assessment of LVEF (in %) is planned over the patient's further study participation.
•5. Data from cycles with anthracycline containing chemotherapy before the start of epoetin treatment are available for retrospective documentation.
•6. Written informed consent of patient covering the retro- and prospective pseudonymous documentation, transmission and analysis of data is available.

•1. Contraindications to Epoetin alfa HEXAL according to the current summary of product characteristics.
•2. Patient has not signed the written informed consent form.
•3. Patient has participated in the same study earlier.
•4. Patient is female and pregnant or breast-feeding.
•5. Physician judges the patient as insufficiently compliant.

发起方